Evaluating Chemoradiation Treatment Response of Glioblastoma Multiforme Brain Tumor Using a Transgenic Mouse Model
MetadataShow full item record
Glioblastoma Multiforme (GBM) is a highly malignant brain tumor that arises in neuroglial cells. GBMs have no known treatment and an extremely high mortality rate. This study was designed to evaluate the effectiveness of five treatments and to explore the presence of a positive synergistic relationship between chemotherapy and radiotherapy. A transgenic mouse model was generated to test the effectiveness of these treatments in vivo. GBMs were induced in the mice brains. The subjects were divided into five treatment groups: temozolomide (TMZ), gemcitabine (GEM), radiation therapy, combined TMZ + radiation and combined GEM + radiation. The control group was given DMSO buffer. Tumor progression was assessed (as an indicator of treatment effectiveness) on anatomical images acquired using Magnetic Resonance Imaging. Scatter plots showing the percentage change in tumor volume were generated to compare the rate of disease progression between treatment groups. The combination of TMZ + radiation showed significant reduction in tumor progression. GEM and GEM + radiation provided the best results, and were shown to decrease the tumor volume below its baseline value. A Kaplan-Meier plot was generated to assess the overall survival of mice. The combination of TMZ + radiation significantly improved survival. GEM + radiation demonstrated the most impressive decrease in volume change. In conclusion, GEM shows the best synergistic relationship with radiotherapy and is a better alternative to other therapies and either treatment alone.